Your email is not valid
Recipient's email is not valid
Submit Close

Your email has been sent.

Click here to send another


What The Gene Patent Ruling Means for Jews

Supreme Court decision will make BRCA mutation testing more accessible

Print Email
People walk past the U.S. Supreme Court building June 13, 2013 in Washington, DC.(Mark Wilson/Getty Images)

In a healthcare system characterized all too often by an adversarial relationship between patients and service providers, yesterday saw a win for patients. The Supreme Court ruled unanimously that human genes cannot be patented.

Myriad Genetics, a molecular diagnostic company based in Salt Lake City, isolated two genes with mutations highly associated with breast and ovarian cancer: BRCA 1 and BRCA 2. Women with these mutations have an 85 percent risk for breast cancer and 50 percent risk for ovarian cancer. Myriad created a test for the mutation. Then they patented the gene itself.

The Association for Molecular Pathology brought the suit against Myriad, under the auspices of their mission “to inform and influence public policy affecting molecular pathology.” The Supreme Court found in their favor, emphasizing that, “Myriad did not create anything,” since a gene is “the product of nature and not product eligible merely because it has been isolated.”

This is a win for all patients, especially women, but in particular, for Ashkenazi women who have more than double the incidence of the mutation—compared to the general population: one in 40 Ashkenazi women have the mutation.

Until now, reports, “The cost of the BRCA test ranges from about $300 to $3,000, depending on whether you get the limited test, in which only a few areas of the gene are evaluated, or the full test, in which hundreds of areas are examined on both genes.”

The Supreme Court’s ruling means that other companies can begin creating their own test, and with Myriad no longer in possession of a patent, the company no longer gets to decide how much the test should cost.

Related: On the Cancer Gene Trail [Vox Tablet]
A Case for Genetic Jewishness [Tablet]

Print Email

Daily rate: $2
Monthly rate: $18
Yearly rate: $180

Tablet is committed to bringing you the best, smartest, most enlightening and entertaining reporting and writing on Jewish life, all free of charge. We take pride in our community of readers, and are thrilled that you choose to engage with us in a way that is both thoughtful and thought-provoking. But the Internet, for all of its wonders, poses challenges to civilized and constructive discussion, allowing vocal—and, often, anonymous—minorities to drag it down with invective (and worse). Starting today, then, we are asking people who'd like to post comments on the site to pay a nominal fee—less a paywall than a gesture of your own commitment to the cause of great conversation. All proceeds go to helping us bring you the ambitious journalism that brought you here in the first place.

Readers can still interact with us free of charge via Facebook, Twitter, and our other social media channels, or write to us at Each week, we’ll select the best letters and publish them in a new letters to the editor feature on the Scroll.

We hope this new largely symbolic measure will help us create a more pleasant and cultivated environment for all of our readers, and, as always, we thank you deeply for your support.

pkbrandon says:

The question is:
are Jewish women a big enough market to lower the price?

tracingthetribe says:

Not only Ashkenazi women, but Sephardic women and Hispanic women (descendants of conversos) also carry BRCA mutations in very significant numbers. Mentioning only “Ashkenazi women” in this article is not helpful.

mikerbiker says:

Your conclusion is not exactly true- Only a small subset of claims of one of many of Myriad’s patents were found invalid.

Myriad spent hundreds of millions of dollars to develop the tests for the breast cancer genes. Strong patent protection is necessary so that biotech companies can achieve a return on their investments. I’m just hoping this ruling doesn’t create disincentives to bringing new therapies and tests to market. I’m not sure it’s a “win for all patients” if such disincentives occur.


Your comment may be no longer than 2,000 characters, approximately 400 words. HTML tags are not permitted, nor are more than two URLs per comment. We reserve the right to delete inappropriate comments.

Thank You!

Thank you for subscribing to the Tablet Magazine Daily Digest.
Please tell us about you.

What The Gene Patent Ruling Means for Jews

Supreme Court decision will make BRCA mutation testing more accessible

More on Tablet:

11 Non-Jewish Celebrities—and 2 Jewish Ones—Show Off Their Hebrew Tattoos

By Marjorie Ingall — You don’t have to be Jewish to sport Hebrew ink. But some of these stars should have thought twice before going under the needle.